International Journal of Infectious Diseases, ISSN 1201-9712, 11/2019, Volume 88, pp. 73 - 79
Severe cases of primary HIV infection have been described in patients presenting with neurological involvement, AIDS defining events or other life-threatening...
Early antiretroviral therapy | Severity | Recent HIV Infection | Acute HIV Infection | Primary HIV Infection | VIRAL LOAD | INFECTIOUS DISEASES | ADULTS | RATIO | AIDS | ANTIRETROVIRAL THERAPY
Early antiretroviral therapy | Severity | Recent HIV Infection | Acute HIV Infection | Primary HIV Infection | VIRAL LOAD | INFECTIOUS DISEASES | ADULTS | RATIO | AIDS | ANTIRETROVIRAL THERAPY
Journal Article
Lancet Infectious Diseases, The, ISSN 1473-3099, 2015, Volume 15, Issue 7, pp. 785 - 792
Summary Background Our objective was to assess therapeutic non-inferiority of dual treatment with lopinavir–ritonavir and lamivudine to triple treatment with...
Infectious Disease | RALTEGRAVIR | INFECTIOUS DISEASES | HIV-1 | Humans | Middle Aged | Male | RNA, Viral - blood | Viral Load | Reverse Transcriptase Inhibitors - adverse effects | HIV Infections - immunology | Deoxycytidine - therapeutic use | Drug Therapy, Combination - adverse effects | Lamivudine - therapeutic use | Ritonavir - therapeutic use | Adult | Anti-HIV Agents - therapeutic use | Female | Maintenance Chemotherapy | Reverse Transcriptase Inhibitors - therapeutic use | Emtricitabine | HIV Protease Inhibitors - adverse effects | Anti-HIV Agents - adverse effects | HIV Infections - virology | CD4 Lymphocyte Count | HIV Protease Inhibitors - therapeutic use | Drug Therapy, Combination - methods | Intention to Treat Analysis | HIV Infections - drug therapy | Lopinavir - therapeutic use | Deoxycytidine - analogs & derivatives | Clinical trials | Antiretroviral drugs | Substance abuse treatment | Laboratories | Human immunodeficiency virus--HIV
Infectious Disease | RALTEGRAVIR | INFECTIOUS DISEASES | HIV-1 | Humans | Middle Aged | Male | RNA, Viral - blood | Viral Load | Reverse Transcriptase Inhibitors - adverse effects | HIV Infections - immunology | Deoxycytidine - therapeutic use | Drug Therapy, Combination - adverse effects | Lamivudine - therapeutic use | Ritonavir - therapeutic use | Adult | Anti-HIV Agents - therapeutic use | Female | Maintenance Chemotherapy | Reverse Transcriptase Inhibitors - therapeutic use | Emtricitabine | HIV Protease Inhibitors - adverse effects | Anti-HIV Agents - adverse effects | HIV Infections - virology | CD4 Lymphocyte Count | HIV Protease Inhibitors - therapeutic use | Drug Therapy, Combination - methods | Intention to Treat Analysis | HIV Infections - drug therapy | Lopinavir - therapeutic use | Deoxycytidine - analogs & derivatives | Clinical trials | Antiretroviral drugs | Substance abuse treatment | Laboratories | Human immunodeficiency virus--HIV
Journal Article
AIDS, ISSN 0269-9370, 11/2015, Volume 29, Issue 17, pp. 2229 - 2233
boosted integrase inhibitors | boosted protease inhibitors | INFECTIOUS DISEASES | NAIVE HIV-1-INFECTED PATIENTS | NON-INFERIORITY TRIAL | CO-FORMULATED ELVITEGRAVIR | INITIAL TREATMENT | OPEN-LABEL | IMMUNOLOGY | HIV-INFECTED PATIENTS | REVERSE-TRANSCRIPTASE INHIBITOR | PROTEASE INHIBITOR | VIROLOGY | LOW-DOSE RITONAVIR | DISOPROXIL FUMARATE | Anti-Retroviral Agents - therapeutic use | Ritonavir - pharmacokinetics | Anti-Retroviral Agents - pharmacokinetics | Humans | Plasma - chemistry | Saquinavir - pharmacokinetics | Ritonavir - therapeutic use | HIV Infections - drug therapy | Treatment Outcome | Antiretroviral Therapy, Highly Active - methods | Saquinavir - therapeutic use
Journal Article
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, ISSN 0305-7453, 06/2019, Volume 74, Issue 6, pp. 1713 - 1717
Objectives: Tropheryma whipplei has been detected in 3.5% of the blood culture-negative cases of endocarditis in Spain. Experience in the management of T....
DIAGNOSIS | INFECTIOUS DISEASES | TRIMETHOPRIM | RESISTANCE | TRIMETHOPRIM/SULFAMETHOXAZOLE | MICROBIOLOGY | PHARMACOLOGY & PHARMACY | INFECTIVE ENDOCARDITIS
DIAGNOSIS | INFECTIOUS DISEASES | TRIMETHOPRIM | RESISTANCE | TRIMETHOPRIM/SULFAMETHOXAZOLE | MICROBIOLOGY | PHARMACOLOGY & PHARMACY | INFECTIVE ENDOCARDITIS
Journal Article
Medicine (United States), ISSN 0025-7974, 2015, Volume 94, Issue 43, p. e1816
The aim of the study was to describe the epidemiologic and clinical characteristics and identify the risk factors of short-term and 1-year mortality in a...
MORTALITY | SURGERY | STATEMENT | DIAGNOSIS | EUROSCORE | MEDICINE, GENERAL & INTERNAL | RISK-FACTORS | MANAGEMENT | CARDIOLOGY | PROGNOSIS | HEALTH-CARE PROFESSIONALS | Heart Valve Diseases - microbiology | Prospective Studies | Humans | Middle Aged | Risk Factors | Male | Endocarditis - microbiology | Endocarditis - diagnosis | Heart Valve Prosthesis - microbiology | Spain - epidemiology | Endocarditis - mortality | Heart Valve Diseases - mortality | Female | Aged | Heart Valve Diseases - diagnosis | Heart | Care and treatment | Usage | Surgery | Infective endocarditis | Research | Health aspects | Risk factors
MORTALITY | SURGERY | STATEMENT | DIAGNOSIS | EUROSCORE | MEDICINE, GENERAL & INTERNAL | RISK-FACTORS | MANAGEMENT | CARDIOLOGY | PROGNOSIS | HEALTH-CARE PROFESSIONALS | Heart Valve Diseases - microbiology | Prospective Studies | Humans | Middle Aged | Risk Factors | Male | Endocarditis - microbiology | Endocarditis - diagnosis | Heart Valve Prosthesis - microbiology | Spain - epidemiology | Endocarditis - mortality | Heart Valve Diseases - mortality | Female | Aged | Heart Valve Diseases - diagnosis | Heart | Care and treatment | Usage | Surgery | Infective endocarditis | Research | Health aspects | Risk factors
Journal Article
Critical Care Medicine, ISSN 0090-3493, 02/2018, Volume 46, Issue 2, pp. 181 - 188
OBJECTIVES:The “Pneumonia Zero” project is a nationwide multimodal intervention based on the simultaneous implementation of a comprehensive evidence-based...
ventilator-associated pneumonia | prevention & control | guideline adherence | intensive care units
ventilator-associated pneumonia | prevention & control | guideline adherence | intensive care units
Journal Article
Clinical Infectious Diseases, ISSN 1058-4838, 03/2018, Volume 66, Issue 6, pp. 825 - 832
Prosthetic valve Candida spp. endocarditis is rare but remains severe, with a 6-month mortality rate of 34%. Liposomal amphotericin B-based "induction"...
Candida | endocarditis | prosthetic valve | DIAGNOSIS | INFECTIOUS DISEASES | MANAGEMENT | MICROBIOLOGY | FUNGAL ENDOCARDITIS | IMMUNOLOGY | GUIDELINE | THERAPY | INFECTIVE ENDOCARDITIS | FLUCONAZOLE
Candida | endocarditis | prosthetic valve | DIAGNOSIS | INFECTIOUS DISEASES | MANAGEMENT | MICROBIOLOGY | FUNGAL ENDOCARDITIS | IMMUNOLOGY | GUIDELINE | THERAPY | INFECTIVE ENDOCARDITIS | FLUCONAZOLE
Journal Article
Current Opinion in Infectious Diseases, ISSN 0951-7375, 02/2009, Volume 22, Issue 1, pp. 28 - 34
Journal Article
Antimicrobial Agents and Chemotherapy, ISSN 0066-4804, 08/2012, Volume 56, Issue 8, pp. 4511 - 4515
Classifications Services AAC Citing Articles Google Scholar PubMed Related Content Social Bookmarking CiteULike Delicious Digg Facebook Google+ Mendeley Reddit...
ANTIBIOTICS | WALL STRESS STIMULON | BACTEREMIA | MICROBIOLOGY | PHARMACOLOGY & PHARMACY | INFECTIVE ENDOCARDITIS | COMBINATION | Endocarditis, Bacterial - drug therapy | Staphylococcal Infections - drug therapy | Fosfomycin - therapeutic use | Fosfomycin - adverse effects | Humans | Methicillin-Resistant Staphylococcus aureus - drug effects | Middle Aged | Male | Drug Synergism | Microbial Sensitivity Tests | Anti-Bacterial Agents - therapeutic use | Fosfomycin - administration & dosage | Female | Aged | Anti-Bacterial Agents - adverse effects | Staphylococcal Infections - microbiology | Daptomycin - adverse effects | Drug Therapy, Combination | Anti-Bacterial Agents - administration & dosage | Daptomycin - administration & dosage | Daptomycin - therapeutic use | Clinical Therapeutics
ANTIBIOTICS | WALL STRESS STIMULON | BACTEREMIA | MICROBIOLOGY | PHARMACOLOGY & PHARMACY | INFECTIVE ENDOCARDITIS | COMBINATION | Endocarditis, Bacterial - drug therapy | Staphylococcal Infections - drug therapy | Fosfomycin - therapeutic use | Fosfomycin - adverse effects | Humans | Methicillin-Resistant Staphylococcus aureus - drug effects | Middle Aged | Male | Drug Synergism | Microbial Sensitivity Tests | Anti-Bacterial Agents - therapeutic use | Fosfomycin - administration & dosage | Female | Aged | Anti-Bacterial Agents - adverse effects | Staphylococcal Infections - microbiology | Daptomycin - adverse effects | Drug Therapy, Combination | Anti-Bacterial Agents - administration & dosage | Daptomycin - administration & dosage | Daptomycin - therapeutic use | Clinical Therapeutics
Journal Article
JAMA, ISSN 0098-7484, 07/2010, Volume 304, Issue 3, pp. 321 - 333
CONTEXT Recent data regarding the consequences of untreated human immunodeficiency virus (HIV) infection and the expansion of treatment choices for...
MEDICINE, GENERAL & INTERNAL | HEPATITIS-B-VIRUS | MYOCARDIAL-INFARCTION | NAIVE HIV-1-INFECTED PATIENTS | DAILY DARUNAVIR/RITONAVIR | EARLY VIROLOGICAL FAILURE | ONCE-DAILY ATAZANAVIR/RITONAVIR | OPPORTUNISTIC INFECTIONS | TWICE-DAILY LOPINAVIR/RITONAVIR | DRUG-RESISTANCE | OPTIMIZED BACKGROUND THERAPY | HIV-1 | Drug Administration Schedule | Anti-Retroviral Agents - administration & dosage | Humans | Treatment Failure | Anti-Retroviral Agents - adverse effects | Adult | HIV Infections - drug therapy | RNA, Viral - blood | CD4 Lymphocyte Count | Viral Load | Antiretroviral drugs | Acquired immune deficiency syndrome--AIDS | Drug therapy | Human immunodeficiency virus--HIV
MEDICINE, GENERAL & INTERNAL | HEPATITIS-B-VIRUS | MYOCARDIAL-INFARCTION | NAIVE HIV-1-INFECTED PATIENTS | DAILY DARUNAVIR/RITONAVIR | EARLY VIROLOGICAL FAILURE | ONCE-DAILY ATAZANAVIR/RITONAVIR | OPPORTUNISTIC INFECTIONS | TWICE-DAILY LOPINAVIR/RITONAVIR | DRUG-RESISTANCE | OPTIMIZED BACKGROUND THERAPY | HIV-1 | Drug Administration Schedule | Anti-Retroviral Agents - administration & dosage | Humans | Treatment Failure | Anti-Retroviral Agents - adverse effects | Adult | HIV Infections - drug therapy | RNA, Viral - blood | CD4 Lymphocyte Count | Viral Load | Antiretroviral drugs | Acquired immune deficiency syndrome--AIDS | Drug therapy | Human immunodeficiency virus--HIV
Journal Article
Journal of the International AIDS Society, ISSN 1758-2652, 11/2014, Volume 17, Issue 4 Suppl 3, pp. 19603 - n/a
Introduction The National AIDS Plan and the Spanish AIDS study group (GESIDA) panel of experts propose “preferred regimens” of antiretroviral treatment (ART)...
Antiretroviral drugs | Costs | Acquired immune deficiency syndrome--AIDS | Drug resistance | Efficiency | Human immunodeficiency virus--HIV | HIV-positive persons | Infeccions per VIH | HIV infections | Persones seropositives | Cost effectiveness | Anàlisi cost-benefici
Antiretroviral drugs | Costs | Acquired immune deficiency syndrome--AIDS | Drug resistance | Efficiency | Human immunodeficiency virus--HIV | HIV-positive persons | Infeccions per VIH | HIV infections | Persones seropositives | Cost effectiveness | Anàlisi cost-benefici
Journal Article
Clinical Infectious Diseases, ISSN 1058-4838, 10/2014, Volume 59, Issue 8, p. 1105
There is an urgent need for alternative rescue therapies in invasive infections caused by methicillin-resistant Staphylococcus aureus (MRSA). We assessed the...
Clinical trials | Staphylococcus infections | Drug resistance | Drug therapy
Clinical trials | Staphylococcus infections | Drug resistance | Drug therapy
Journal Article
Clinical Infectious Diseases, ISSN 1058-4838, 06/2016, Volume 62, Issue 12, p. 1578
It has been suggested that routine CD4 cell count monitoring in human immunodeficiency virus (HIV)-monoinfected patients with suppressed viral loads and CD4...
Human papillomavirus | Human immunodeficiency virus--HIV | Probability | Glycoproteins | Immune system
Human papillomavirus | Human immunodeficiency virus--HIV | Probability | Glycoproteins | Immune system
Journal Article
PLoS ONE, ISSN 1932-6203, 05/2016, Volume 11, Issue 5, p. e0155245
Background The relationship between host microRNAs (miRNA), viral control and immune response has not yet been elucidated in the field of HIV. The aim of this...
EFFECTOR | T-CELL DIFFERENTIATION | ACTIVATION | BIOINFORMATICS | MEMORY | MULTIDISCIPLINARY SCIENCES | SENSITIVITY | CD4(+) | ABSENCE | EXPRESSION | MIR-181A | Anti-HIV Agents - pharmacology | Reproducibility of Results | HIV Infections - genetics | Humans | Middle Aged | Male | MicroRNAs - metabolism | Gene Expression Profiling | Disease Progression | Immunity - drug effects | HIV Infections - immunology | HIV Infections - pathology | Adult | Anti-HIV Agents - therapeutic use | Female | HIV Infections - drug therapy | MicroRNAs - genetics | CD8-Positive T-Lymphocytes - immunology | Real-Time Polymerase Chain Reaction | Complications and side effects | Care and treatment | MicroRNA | Analysis | Influence | Cellular signal transduction | Research | HIV infection | Enrichment | Controllers | Antiretroviral drugs | Immune response | Control methods | CD8 antigen | Genes | MiRNA | Lymphocytes T | CD3 antigen | T cell receptors | Gene expression | CD28 antigen | Ribonucleic acid--RNA | Disease control | Acquired immune deficiency syndrome--AIDS | Lymphocytes | Human immunodeficiency virus--HIV | Transduction | Apoptosis | Immune system | RNA | Ribonucleic acid | AIDS | HIV | Acquired immune deficiency syndrome | Human immunodeficiency virus
EFFECTOR | T-CELL DIFFERENTIATION | ACTIVATION | BIOINFORMATICS | MEMORY | MULTIDISCIPLINARY SCIENCES | SENSITIVITY | CD4(+) | ABSENCE | EXPRESSION | MIR-181A | Anti-HIV Agents - pharmacology | Reproducibility of Results | HIV Infections - genetics | Humans | Middle Aged | Male | MicroRNAs - metabolism | Gene Expression Profiling | Disease Progression | Immunity - drug effects | HIV Infections - immunology | HIV Infections - pathology | Adult | Anti-HIV Agents - therapeutic use | Female | HIV Infections - drug therapy | MicroRNAs - genetics | CD8-Positive T-Lymphocytes - immunology | Real-Time Polymerase Chain Reaction | Complications and side effects | Care and treatment | MicroRNA | Analysis | Influence | Cellular signal transduction | Research | HIV infection | Enrichment | Controllers | Antiretroviral drugs | Immune response | Control methods | CD8 antigen | Genes | MiRNA | Lymphocytes T | CD3 antigen | T cell receptors | Gene expression | CD28 antigen | Ribonucleic acid--RNA | Disease control | Acquired immune deficiency syndrome--AIDS | Lymphocytes | Human immunodeficiency virus--HIV | Transduction | Apoptosis | Immune system | RNA | Ribonucleic acid | AIDS | HIV | Acquired immune deficiency syndrome | Human immunodeficiency virus
Journal Article